Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Vermersch, Patrick ^a   Benrabah, Rabah ^b   Schmidt, Nicolas ^c   Zéphir, Hélène ^a   Clavelou, Pierre ^d   Vongsouthi, Cyrille ^e   Dubreuil, Patrice ^f,g,h,i   Moussy, Alain ^f   Hermine, Olivier ^f,j  

^a UNIV LILLE   (France)

^b Private Practice   (France)

^c Private Practice   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e Private Practice   (France)

^f AB Science SA   (France)

^g INSERM   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j CNRS   (France)

more..

Author keywords

Masitinib; Mast cells; Multiple sclerosis; Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis; Tyrosine kinase inhibitor

Indexed keywords

ANALGESIC AGENT; CETIRIZINE; MASITINIB; NARCOTIC ANALGESIC AGENT; PLACEBO;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXPANDED DISABILITY STATUS SCALE; EXPLORATORY RESEARCH; FEMALE; HAND FOOT SYNDROME; HUMAN; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; URTICARIA;

ADMINISTRATION, ORAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; PLACEBO EFFECT; THIAZOLES; TREATMENT OUTCOME;

EID: 84861980282     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-36     Document Type: Article

References (32)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911. 10.1212/WNL.46.4.907, 8780061.
2. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430-1438. 10.1056/NEJM200011163432001, 11078767.
3. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi MMX, De Sa J. Primary progressive multiple sclerosis. Brain 1997, 120(Pt 6):1085-1096.
4. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, Borge L, Hajem B, Lermet A, Sippl W, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009, 4:e7258. 10.1371/journal.pone.0007258, 2746281, 19789626.
5. Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009, 64:1194-1201. 10.1111/j.1398-9995.2009.02122.x, 19614621.
6. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85:921-925. 10.1002/ajh.21894, 21108325.
7. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011, 3:16. 10.1186/alzrt75, 3226277, 21504563.
8. Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, Gineste P, Guy L, Mansfield CD, Moussy A, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009, 11:R95. 10.1186/ar2740, 2714151, 19549290.
9. Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R. Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A 2008, 105:18053-18057. 10.1073/pnas.0809479105, 2584714, 19004805.
10. Silverman AJ, Sutherland AK, Wilhelm M, Silver R. Mast cells migrate from blood to brain. J Neurosci 2000, 20:401-408.
11. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12. 10.1016/j.jneuroim.2003.10.041, 14698841.
12. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009, 31:455-465. 10.1007/s00281-009-0182-3, 19730864.
13. Brown MA, Tanzola MB, Robbie-Ryan M. Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol 2002, 38:1373-1378. 10.1016/S0161-5890(02)00091-3, 12217411.
14. Theoharides TC, Kempuraj D, Kourelis T, Manola A. Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci 2008, 1144:74-82. 10.1196/annals.1418.029, 19076366.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127. 10.1002/ana.1032, 11456302.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452. 10.1212/WNL.33.11.1444, 6685237.
18. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999, 122(Pt 5):871-882.
19. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Administration and scoring manual for the multiple sclerosis functional composite meaure (MSFC) 1999, Demos, New York.
20. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000, 343:938-952. 10.1056/NEJM200009283431307, 11006371.
21. Bebo BF, Yong T, Orr EL, Linthicum DS. Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J Neurosci Res 1996, 45:340-348. 10.1002/(SICI)1097-4547(19960815)45:4<340::AID-JNR3>3.0.CO;2-9, 8872894.
22. Brenner T, Soffer D, Shalit M, Levi-Schaffer F. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci 1994, 122:210-213. 10.1016/0022-510X(94)90300-X, 7517440.
23. Kinet JP. The essential role of mast cells in orchestrating inflammation. Immunol Rev 2007, 217:5-7. 10.1111/j.1600-065X.2007.00528.x, 17498047.
24. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC. Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303:1061-1066. 10.1124/jpet.102.038497, 12438528.
25. Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC. Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. J Neuroimmunol 2003, 145:18-26. 10.1016/j.jneuroim.2003.09.004, 14644027.
26. Skaper SD, Facci L, Romanello S, Leon A. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem 1996, 66:1157-1166.
27. Encinas JM, Manganas L, Enikolopov G. Nitric oxide and multiple sclerosis. Curr Neurol Neurosci Rep 2005, 5:232-238. 10.1007/s11910-005-0051-y, 15865889.
28. Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004, 63:1439-1445. 10.1212/01.WNL.0000142043.32578.5D, 15505162.
29. Bidri M, Feger F, Varadaradjalou S, Ben Hamouda N, Guillosson JJ, Arock M. Mast cells as a source and target for nitric oxide. Int Immunopharmacol 2001, 1:1543-1558. 10.1016/S1567-5769(01)00097-2, 11515818.
30. Chu CL, Lowell CA. The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol 2005, 175:2880-2889.
31. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yarlagadda M, Vanhaesebroeck B, Ray A, Ray P. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 2008, 14:565-573. 10.1038/nm1766, 18454155.
32. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. 10.1038/nature10251, 3182531, 21833088, The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2.